leisure time -WSS

leisure time

author：comprehensive 2025-09-14 21:35:46 - browse：547

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： STAT Virtual Event: The State of Biosimilars: What to Watch

WSS

AI can’t replace a physician’s gut feeling

STAT Summit: Biotech founders on deal

AI can’t replace a physician’s gut feeling

Group opposing PBM reform sets lobbying record

WHO calls for emergency meeting on new China virus, as cases spread

Sanofi seeks simpler, safer CRISPR sickle cell cure

hotspot

leisure time

entertainment

Medicare details structure of new drug price negotiation program

Beam Therapeutics to lay off 20% of its staff, re

Medicare details structure of new drug price negotiation program

Senate committee scrutinizes Medicare Advantage brokers

The cancer drug shortage isn’t new — and neither are the solutions

A public scorecard can help hold safety

Psychedelics group wrestles with new pharma identity

How climate

Medicare proposal to cover medical devices draws a mixed reaction

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Wikipedia

How climate

Why hospitals are withdrawing from US News rankings

Medicare has a new plan to address drug shortages

STAT Virtual Event: The State of Biosimilars: What to Watch

Sanders adds drug shortage policies to pandemic preparedness bill

HHS leader on health, climate change and biopharma emissions

leisure time

focus

hotspot

hotspot